Rivastigmine

Generic Name: Rivastigmine

Brand Names: Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₂N_₂O_₂

CAS Number: 123441-03-2

Unique Ingredient Identifier: PKI06M3IW0

Background: Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication: For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions: Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease

Associated Therapies: -

Clinical Trials

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Phase 2

Recruiting

Conditions: Anticholinergic Toxicity

Interventions: Drug: Placebo
Drug: Rivastigmine

First Posted Date: 2024-05-06

Last Posted Date: 2024-11-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 42

Registration Number: NCT06399679

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Rivastigmine for Antimuscarinic Delirium

Phase 2

Not yet recruiting

Conditions: Anticholinergic Toxicity

Interventions: Drug: Placebo
Drug: Rivastigmine

First Posted Date: 2024-04-24

Last Posted Date: 2024-11-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 42

Registration Number: NCT06382649

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Placebo oral tablet
Drug: Rivastigmine
Drug: Reboxetine

First Posted Date: 2019-05-21

Last Posted Date: 2020-06-16

Lead Sponsor: University of Oxford

Target Recruit Count: 107

Registration Number: NCT03957174

Locations: 🇬🇧
Dept of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine

First Posted Date: 2016-12-12

Last Posted Date: 2024-05-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT02989402

Locations: 🇮🇳
Novartis Investigative Site, Kolkata, West Bengal, India

Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

Phase 3

Completed

Conditions: Progressive Supranuclear Palsy (PSP)

Interventions: Drug: Placebo
Drug: Rivastigmine

First Posted Date: 2016-07-21

Last Posted Date: 2023-07-20

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 106

Registration Number: NCT02839642

Locations: 🇫🇷
Service de Neurologie et Pathologie du Mouvement Hôpital de La Timone, Marseille Cedex 5, France

Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD

Phase 4

Completed

Conditions: Alzheimer Disease
CVA (Cerebrovascular Accident)

Interventions: Drug: Rivastigmine

First Posted Date: 2015-05-14

Last Posted Date: 2021-03-05

Lead Sponsor: National Neuroscience Institute

Target Recruit Count: 100

Registration Number: NCT02444637

Locations: 🇸🇬
National Neuroscience Institute, Singapore, Singapore

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles

Not Applicable

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine

First Posted Date: 2014-02-14

Last Posted Date: 2015-05-14

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 70

Registration Number: NCT02063269

Locations: 🇰🇷
Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Phase 4

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Placebo (for rivastigmine)
Drug: Rivastigmine

First Posted Date: 2013-05-17

Last Posted Date: 2018-10-09

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 91

Registration Number: NCT01856738

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱
Atrium Medical Center, Heerlen, Netherlands
🇳🇱
University Medical Center St Radboud, Nijmegen, Netherlands

and more 1 locations

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: RO4602522
Drug: Placebo
Drug: Donepezil
Drug: Memantine
Drug: Rivastigmine
Drug: Galantamine

First Posted Date: 2012-09-03

Last Posted Date: 2017-05-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT01677754

Locations: 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇨🇦
Vancouver Island Health Authority, Victoria, British Columbia, Canada
🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

and more 139 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy